- Biotechnology company Immutep (IMM) closes its share purchase plan (SPP) which is oversubscribed by more than $2 million
- Following strong demand from shareholders, Immutep has increased the size of the SPP to accept the full amount of applications
- Money raised from the SPP and a recent $60 million placement will go towards ongoing immune-oncology clinical development programs, a pre-clinical autoimmune disease program and general working capital
- The company says it expects the 13,799,149 new shares will be issued on July 23 and will commence trading on the ASX on July 26
- Immutep is up 1.5 per cent, trading at 50.8 cents at 12:45 pm AEST